A shadow market for unlicensed slimming drugs is being driven by social media fitness personalities and sellers on communication apps, according to new investigations.
Experimental Drug Gaining Traction Via Social Media
The experimental drug, which is still in research studies, is being promoted by online personalities for its alleged weight-reducing effects. Followers are encouraged to message these profiles privately for supplier links, while also obtaining discount codes.
Thriving Commerce on Social Networks
Separately, a robust market exists on messaging services, where groups with thousands of members share comparison images, administration instructions and claims of rapid British shipping. Sellers promote the drug there before directing customers to other platforms for purchases.
Understanding The Experimental Drug
Retatrutide is an investigational injectable created by American pharmaceutical company Eli Lilly. The treatment affects three gut hormones – GLP-1, GIP and glucagon. Preliminary studies indicate it could help individuals reduce up to 25% of their total weight. Nicknamed the “triple G”, the drug is being promoted digitally as the successor to Ozempic.
Healthcare Experts Express Worries
However, physicians and pharmacists have cautions that the sale of what remains an unapproved medication in the United Kingdom is worrisome and could result in users injecting products of unknown origin.
Several experts stated the popularity for the experimental drug could be connected to the increasing cost of licensed slimming products such as Mounjaro.
Regulatory Position and Implementation
Marketing the unapproved drug on TikTok or Telegram is illegal in the UK, as it is an unapproved medication that must not be marketed or supplied for personal consumption under the Human Medicines Regulations 2012.
Several influencers attempt to circumvent the regulations by referring to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted drug, but promotion and supply can still violate medicines, marketing, and customer laws, risking fines, prosecution or prison.
Service Response and Material Removal
Based on the social media company, the service has taken down problematic material and banned related hashtags and search suggestions. The company stated it was dedicated to keeping the service secure and allocating resources in enhancing enforcement strategies.
Digital Marketplace Operations
Research also found groups with up to 9,000 participants selling retatrutide using Telegram's integrated discovery tool, which operates like a public directory. Entering “retatrutide” instantly brings up channels with thousands of members, filled with photos of slimming results, positive testimonials and detailed instructions for mixing or administering at home.
After moments of entering one group, a vendor posted contact information, where the majority of transactions occur. The seller provided an instruction manual and promised delivery within 48 hours. When questioned whether the substance was authentic, one vendor said: “You can’t be sure.” Another provided a image of a supposed testing documentation. Not one asked about weight, health issues or previous experience.
Item Information and Pricing
Within these groups, messages show dark colored parcels with Royal Mail labels, stating to contain fresh supplies. One message stated: “It took eight of us to load them this morning.”
Customers can choose between dry substance containers, mixed at residence with purified liquid, or pre-filled injectors typically priced at £160 for 20mg. When asked how long a pen should be used, vendors give conflicting responses varying between a few weeks to “depends on your body”.
Platform Moderation and Safety Actions
A representative for the messaging service stated it actively moderated harmful material on its platform including content that promoted the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.
Healthcare Professional Warnings
“Individuals are injecting materials they cannot confirm. Although the science behind this drug is valid, these digital products may not include what they advertise,” said a pharmacy expert, the head of pharmaceutical services at Chemist4U.
A medical professional of an online medical service linked the increase in demand to current cost increases for authorized weight-loss medications such as Mounjaro. “With costs increasing, individuals are turning to social media. But counterfeit injections are extremely dangerous. You can’t be certain what’s contained or whether the environment they were produced in was sterile,” she explained.
Her team has already encountered patients injured by self-injection from unconfirmed suppliers. “We understand the disappointment, but buying from Telegram or communication platforms is gambling with your well-being,” said Wyllie. “These substances could be contaminated or improperly measured.”
Producer Statement
A spokesperson from Eli Lilly said retatrutide was in phase 3 clinical trials and had not been evaluated or authorized by any government authority globally. “Consequently at this point no one can sell [it] for human use,” they explained, adding that any product “falsely representing itself as a company experimental substance not yet authorized … may subject patients to potentially significant health risks”.
